- Home
- ARTW vs BLRX Comparison
ARTW vs BLRX Comparison
Compare ARTW & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARTW | BLRX |
|---|---|---|
| Founded | 1956 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 12.6M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | ARTW | BLRX |
|---|---|---|
| Price | $2.36 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 47.4K | 15.9K |
| Earning Date | 02-04-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $22,975,408.00 | $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.75 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.43 | $2.30 |
| 52 Week High | $4.71 | $7.77 |
Technical Indicators
Market Signals| Indicator | ARTW | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.32 | 45.32 |
| Support Level | $2.11 | $2.90 |
| Resistance Level | $2.44 | $3.20 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 13.83 | 20.00 |
Price Performance
Historical ComparisonAbout ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.